Pharmaceutical composition containing beta2 agonists and steroids, and uses thereof

A technology of β2 receptors and compositions, applied in the direction of drug combination, drug delivery, medical preparations containing active ingredients, etc.

Inactive Publication Date: 2009-05-20
SHENYANG PHARMA UNIVERSITY
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The pharmaceutical composition of trabutanterol or mabuterol and fluticasone propionate has not been reported for the treatment of asthma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing beta2 agonists and steroids, and uses thereof
  • Pharmaceutical composition containing beta2 agonists and steroids, and uses thereof
  • Pharmaceutical composition containing beta2 agonists and steroids, and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 - Aerosol composition for metered dose inhaler

[0025]

[0026]

Embodiment 2

[0027] Example 2 - Inhalation powder aerosol

[0028]

[0029] Preparation process: tetrabuterol hydrochloride or mapbuterol hydrochloride and fluticasone propionate are respectively ground into powder with a particle size of 5 μm through a supersonic jet mill at high speed. The medicinal carrier lactose is pulverized into a powder with a particle size of 120 μm by the main machine of the horizontal air-sorting pulverizer, and then the same amount of ultrafine dry powder of the above-mentioned tetrabuterol hydrochloride or mapbuterol hydrochloride and the medicinal carrier is prepared. Incrementally mix well and fill in capsules.

Embodiment 3

[0031]

[0032] Preparation process: tetrabuterol hydrochloride or mapbuterol hydrochloride and fluticasone propionate are respectively ground into powder with a particle size of 5 μm through a supersonic jet mill at high speed. The medicinal carrier lactose and poloxamer are pulverized into a powder with a particle size of 120 μm by a ball mill, and then the superfine dry powder of the above-mentioned tetrabuterol hydrochloride or mapbuterol hydrochloride and the medicinal carrier is prepared by equal increment method. Mix well and fill in capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the medicine technical field, and relates to a pharmaceutical composition of a beta2 receptor agonist and steroid and application thereof, in particular to a pharmaceutical composition of tranditerol or salt thereof, or mabuterol or salt thereof, and fluticasone propionate and application thereof, wherein the mixture ratio of the tranditerol or the salt thereof to the mabuterol or the salt thereof to the fluticasone propionate is 10 to 1-1 to 10,000; and the composition can be a composition which can be atomized in respirable mode, and can be used for preparing an aerosol inhalant and an aerosol. The composition can be prepared into capsules and other formulations with other auxiliary materials after the composition is prepared into dried powder with pharmaceutically acceptable carriers. The composition can significantly improve pulmonary function, and can control obstructive or phlogistic airway diseases or slow down depravation of the diseases. The composition can be used for preparing medicaments for salving and treating the obstructive or phlogistic airway diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to beta 2 The pharmaceutical composition of receptor agonist and steroid and application thereof, specifically relates to the pharmaceutical composition of trabutanterol or its salt or mabuterol or its salt and fluticasone propionate and its application in the treatment of inflammatory or obstructive pneumothorax use in road diseases. Background technique [0002] Trabutinaterol, especially in the form of its hydrochloride salt, is a bronchodilator used in the treatment of inflammatory or obstructive airway diseases. Mabuterol, especially in the form of its hydrochloride salt, is a bronchodilator for the treatment of asthma. It has a stronger relaxing effect on airway smooth muscle, an increase in airway resistance induced by histamine, and an inhibitory effect on experimental asthma than albuterol , The duration is also long, and no tolerance is seen. Fluticasone propionate, 6α,9α...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61K31/137A61K9/72A61K9/12A61P11/00A61P11/06
Inventor 王东凯崔文奇
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap